Cabozantinib: Phase II started

Exelixis said investigators at the Memorial Sloan-Kettering Cancer Center began an open-label, U.S. Phase II trial to evaluate 60 mg oral cabozantinib daily in about 25 NSCLC patients with KIF5B-RET oncogenic fusion protein or related variant RET fusions in their tumors. An NDA is under FDA review for cabozantinib to treat progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC), with a Nov. 29 PDUFA date. The compound has Orphan Drug designation in the U.S. to treat follicular, medullary and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. ...